Risk of heart failure with the use of thiazolidinediones within a medicaid population

P and T

Volumn 30, Issue 5, 2005, Pages 273-281

  Shaya, Fadia T ^a   Shin, James Y ^b   Mullins, C Daniel ^b   El Khoury, Antoine C ^c   Garber, Howard ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH AFRICA   (South Africa)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Heart failure; Medicaid; Metformin; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEDICAID; PRESCRIPTION;

EID: 19544365090     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Web-Based Injury Statistics Query and Reporting System (WISQARS). Leading Causes of Death Reports, 1999-2001. Centers for Disease Control and Prevention/National Center for Injury Prevention and Control. Available at: http://webapp.cdc.gov/sasweb/ncipc/leadcaus10.html. Accessed September 12, 2003.
2. Centers for Disease Control and Prevention, National Institutes of Health: Healthy People 2010: Objectives for Improving Health. 2000, pp 5.3-5.39. Available at: www.health.gov.
3. Oki JC, IsleyWL Diabetes mellitus. In: DiPiro JT, Talbert RL, Yee GC, et al (eds). Pharmacotherapy: A Pathophysiologic Approach, 5th ed. New York: McGraw-Hill, 2002:1335-1358.
4. HenneyJE. New type 2 diabetes drugs. JAMA 1999;282(10):932.
5. He J, Ogden LG, Bazzano L, et al. Risk factors for congestive heart failure in U.S. men and women: NHANESI [National Health and Nutrition Examination Survey] epidemiologic follow-up study. Arch Intern Med 2001;161(7):996-1002.
6. Aronow WS, Ahn C. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest 1999;155(3): 867-868.
7. Bauters C, Lamblin N, McFadden EP, et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003;2(1):1.
8. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20(2):301-306.
9. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347(18):1397-1402.
10. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986: Evidence for increasing population prevalence. Arch Intern Med 1990;150: 769-773.
11. Alexander M, Grumbach K, Selby J, et al. Hospitalization for congestive heart failure: Explaining racial differences. JAMA 1995;274(13):1037-1042.
12. Shen JJ, Wan TTT, Perlin JB. An exploration of the complex relationship of socioecologic factors in the treatment and outcomes of acute myocardial infarction in disadvantaged populations. Health Serv Res 2001;34(4);711-732.
13. Maryland Medicaid eHealth Statistics. Maryland Department of Health and Mental Hygiene. Available at: www.chpdm-ehealth.org/eligibility/index.cfm. Accessed August 10, 2004.
14. Ebell MH, Smith M, Kruse JA, et al. Effect of race on survival following in-hospital cardiopulmonary resuscitation. J Fam Pract 1995;40(6):571-577.
15. Lillie-Blanton M, Parsons PE, Gayle H, Dievler A. Racial differences in health: Not just black and white but shades of grey. Ann Rev Pub Health 1996;17:411-448.
16. Prescribing information for Glucophage® (metformin). Princeton, NJ: Bristol-Myers Squibb: March 2004.
17. Prescribing information for Actos® (pioglitzaone). Indianapolis, IN: Eli Lilly; December 2003.
18. Prescribing information for Avandia® (rosiglitazone). Research Triangle Park, NC: Glaxo SmithMne; August 2004.
19. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clinic Proc 2003;78: 1088-1091.
20. Page RL, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone: Case report and literature review. Pharmacotherapy 2003;23(7):945-954.
21. Heart Disease and Stroke Statistics-2004 Update. Dallas, TX: American Heart Association; 2003.
22. Kalon KLH, Pinsky JL, Kannel WB, Levy D.The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22[Suppl A]:6A-13A.
23. Hunt SA, Baker DW, Chin MH, et al. American College of Cardiology/American Heart Association guidelines for the evaluation and management of chronic heart failure in the adult. Bethesda, MD: American College of Cardiology Foundation; 2001.
24. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations. Am J Cardiol 2003;91(Suppl):18F-40F.
25. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study. Diabetes Care 2003:26(11):2983-2989.
26. Nuse JB. Overview of current therapeutic options in type 2 diabetes. Diabetes Care 1999;22(Suppl 3):C65.
27. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351(11): 1106-1118.
28. U.S. Census Bureau. Census 2000 Summary File 4. Available at: www.census.gov. Accessed August 16, 2004.
29. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by nonsteroidal anti-inflammatory drug use: A consensus statement using a meta-analysis approach. Ann Rheum Dis 2004;63(7):759-766.
30. Dukes MNG, Aronson JK (eds). Meyler's Side Effects of Drugs, 12th ed. Amsterdam, The Netherlands: Elsevier Science Publishers BV, 1992.